Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.64 USD

44.64
16,427,322

-0.21 (-0.47%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $44.65 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $50.31 in the latest trading session, marking a +0.3% move from the prior day.

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

by Zacks Equity Research

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

by Zacks Equity Research

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

by Zacks Equity Research

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

by Zacks Equity Research

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

by Zacks Equity Research

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Avidity (RNA) Expands Collaboration With BMY, Shares Rise

by Zacks Equity Research

Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.

Ekta Bagri headshot

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

by Ekta Bagri

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment

by Zacks Equity Research

Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

by Zacks Equity Research

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.

Company News for Nov 21, 2023

by Zacks Equity Research

Companies in The News Are: NVDA, BMY, PNM, ZM

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

by Zacks Equity Research

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress

by Zacks Equity Research

Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

by Zacks Equity Research

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.

Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

by Zacks Equity Research

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

by Zacks Equity Research

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated

by Zacks Equity Research

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.